Clinical trialNCT04391309TerminatedPhase 2Interventional

COVID-19 and Anti-CD14 Treatment Trial

SponsorNational Institute of Allergy and Infectious Diseases (NIAID)Enrollment49Coronavirus Disease 2019 (COVID-19)Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This study aims to address the following objectives: 1. To determine the efficacy of IC14, an anti-CD14 chimeric monoclonal antibody, in patients hospitalized with respiratory disease and hypoxemia due to SARS-CoV-2, in terms of improving the time to resolution of disease. 2. To determine the efficacy of IC14 in reducing the severity of respiratory disease in patients hospitalized with respiratory disease due to SARS-CoV-2. 3. To determine the safety of IC14 in patients hospitalized with respiratory disease due to SARS-CoV-2.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Mark M. Wurfel, MD, PhD
University of Washington: Division of Pulmonary, Critical Care and Sleep Medicine
Study Chair
clinicaltrials.gov ↗
Thomas R. Martin, MD
University of Washington: Division of Pulmonary, Critical Care and Sleep Medicine
Study Chair
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

5 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Sarasota Memorial Health Care System
Sarasota, Florida, United States
Harborview Medical Center
Seattle, Washington, United States
Swedish Medical Center
Seattle, Washington, United States
University of Washington Medical Center-Montlake
Seattle, Washington, United States
Virginia Mason Medical Center
Seattle, Washington, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Anti-CD14Remdesivir →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 12 Apr 2021
Primary completion: 4 Feb 2022
Completion: 4 Feb 2022
Last update posted: 26 Jun 2023
Registered enrollment: 49
Registry id: NCT04391309

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.